Cell Therapeutics to reacquire rights to two anti-cancer compounds The Pharma Letter Cell Thera is currently accruing patients into a Phase III trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the USA. Cell Therapeutics, Novartis ... Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer ... |
